Mucolipin-1 (F8F9Q) Rabbit mAb #27748
- WB
- IP
- IF
Supporting Data
REACTIVITY | H |
SENSITIVITY | Endogenous |
MW (kDa) | 35-40, 65 |
Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Immunoprecipitation | 1:200 |
Immunofluorescence (Immunocytochemistry) | 1:200 - 1:800 |
Storage
Protocol
Specificity / Sensitivity
Mucolipin-1 (F8F9Q) Rabbit mAb recognizes endogenous levels of total mucolipin-1 protein. This antibody detects the carboxyl terminal fragment produced following posttranslational cleavage.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human mucolipin-1 protein.
Background
Mucolipin-1 (MCOLN1, TRPML1), a member of the transient receptor potential ion channel superfamily, is a lysosomal/late endosome Ca2+ efflux channel that is important in lysosomal biogenesis (1,2). Mutations in the mucolipin-1 gene are responsible for the human lysosomal storage disease mucolipidosis type IV (MLIV), an autosomal recessive neurodegenerative disease (3). Mucolipin-1 is synthesized as a 580-amino acid protein with six transmembrane domains but can undergo cleavage in the long luminal loop between the first two transmembrane domains (4,5). Mucolipin-1 activity has been linked to autophagy and lysosomal biogenesis. Calcium influx through mucolipin-1 activates CaMKKβ and AMPK, which activate the autophagy kinase ULK1 (6). Calcium influx is also associated with activation of the calcium-dependent phosphatase calcineurin which can trigger activation of TFEB, a key transcription factor regulating autophagy and lysosomal biogenesis (7,8). Mucolipin-1 activity is upregulated by cellular stress, including reactive oxygen species (ROS) (7). Phosphorylation of mucolipin-1 by mTOR results in reduced channel activity and autophagic flux (9). Loss of mucolipin-1 or pharmacological inhibition suppresses autophagy and can reduce tumor growth and metastasis in non-small cell lung cancer and triple-negative breast cancer, suggesting the use of mucolipin-1 antagonists for cancer therapy (10-12).
- Zeevi, D.A. et al. (2007) Biochim Biophys Acta 1772, 851-8.
- Cheng, X. et al. (2010) FEBS Lett 584, 2013-21.
- Mirabelli-Badenier, M. et al. (2015) Metab Brain Dis 30, 681-6.
- Kiselyov, K. et al. (2005) J Biol Chem 280, 43218-23.
- Miedel, M.T. et al. (2006) J Biol Chem 281, 12751-9.
- Scotto Rosato, A. et al. (2019) Nat Commun 10, 5630.
- Zhang, X. et al. (2016) Nat Commun 7, 12109.
- Zhang, X. et al. (2016) Autophagy 12, 1954-1955.
- Onyenwoke, R.U. et al. (2015) Biochem J 470, 331-42.
- Yin, C. et al. (2019) Cancer Manag Res 11, 8607-8617.
- Xu, M. et al. (2019) Cell Calcium 79, 80-88.
- Yang, Y. et al. (2020) Cells 9, 2682-2688.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.